Lorlatinib in the treatment of ALK-positive non-small cell lung cancer

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Due to the advent of targeted drugs in the treatment of ALK-positive non-small cell lung cancer, it has now become possible to prescribe treatment that is more effective and less toxic than chemotherapy. This review focuses on the latest approved third-generation ALK inhibitor, lorlatinib. The data of clinical studies, confirming the effectiveness of the drug both in the first and subsequent lines of therapy, as well as the place of the drug in accordance with currently accepted clinical guidelines are presented. A clinical observation demonstrating the effectiveness of the drug in a patient with ALK-positive non-small cell lung cancer in the second line of therapy is discussed.

Full Text

Restricted Access

About the authors

Olga O. Gordeeva

Lopukhin Federal Research and Clinical Center of Physical and Chemical Medicine of Federal Medical and Biological Agency

Author for correspondence.
Email: gordeeva.o@rcpcm.org
ORCID iD: 0000-0002-8266-0218

Cand. Sci. (Med.), Oncologist, Chemotherapist

Russian Federation, Moscow

N. A. Meshcheryakova

National Medical Research Center of Oncology. N.N. Blokhin

Email: gordeeva.o@rcpcm.org
Russian Federation, Moscow

A. A. Meshcheryakov

Lopukhin Federal Research and Clinical Center of Physical and Chemical Medicine of Federal Medical and Biological Agency

Email: gordeeva.o@rcpcm.org
ORCID iD: 0000-0002-6009-653X
Russian Federation, Moscow

References

  1. Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol. 2002;29:3–9. doi: 10.1053/sonc.2002.35642.
  2. Paez J.G., Janne P.A., Lee J.C., et al EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (Wash DC). 2004;304:1497–500. doi: 10.1126/science.1099314.
  3. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–66. doi: 10.1038/nature05945.
  4. Alice T. Shaw, Beow Y. Yeap, Mari Mino-Kenudson, et al. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK. J Clin Oncol. 2009;27:4247–53. doi: 10.1200/JCO.2009.22.6993.
  5. Ming Sound Tsao, Fred R. Hirsch, Yasushi Yatabe. IASLC atlas of ALK testing in lung cancer, 2013.
  6. Benjamin J. Solomon et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. N Engl J Med. 2014;371:2167–77. doi: 10.1056/NEJMoa1408440.
  7. Gainor J.F., Dardaei L., Yoda S., et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016;6(10):1118–33. doi: 10.1158/2159-8290.CD-16-0596.
  8. Johnson T.W., Richardson P.F., Bailey S., et al: Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–44. doi: 10.1021/jm500261q.
  9. Sun S., Pithavala Y.K., Martini J.-F., et al. Evaluation of lorlatinib cerebrospinal fluid concentrations in relation to target concentrations for Anaplastic Lymphoma Kinase (ALK) inhibition. J Clin Pharmacol. 2022;62:1170–76. doi: 10.1002/jcph.2056.
  10. Chen W., Jin D., Shi Y., et al: The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics of lorlatinib in the brain. Cancer Med. 2020;9:4350–59. doi: 10.1002/cam4.3061.
  11. Solomon B.J., Besse B., Bauer T.M., et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–67. doi: 10.1016/S1470-2045(18)30649-1.
  12. Bauer T.M., Felip E., Solomon B.J., et al. Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist. 2019;24(8):1103–1010. doi: 10.1634/theoncologist.2018-0380.
  13. Felip E., Shaw A.T., Bearz A., et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021;32(5):620–30. doi: 10.1016/j.annonc.2021.02.012.
  14. Shaw A.T., Solomon B.J., Besse B., et al. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2019;37(16):1370–79. doi: 10.1200/JCO.18.02236.
  15. Peters S., Shaw A.T., Besse B., et al. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. Lung Cancer. 2020;144:10–9. doi: 10.1016/j.lungcan.2020.02.011.
  16. Baldacci S., Besse B., Avrillon V., et al. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. Eur J Cancer. 2022;166:51–9. doi: 10.1016/j.ejca.2022.01.018.
  17. Лактионов К.К., Реутова Е.В., Крутелева С.Ю., Антонова Е.Ю. Эффективность лорлатиниба в лечении пациентов с ALK- позитивным немелкоклеточным раком легкого при прогрессировании на кризотинибе: собственный опыт применения. Медицинский совет. 2021;(20):62–7. [Laktionov K.K., Reutova E.V., Kruteleva S.Yu., Antonova E.Yu. Efficacy of lorlatinib in the treatment of patients with ALK-positive non-small cell lung cancer progressing on crizotinib: own experience. Meditsinskii sovet. 2021;(20):62–7. (In Russ.)].
  18. Shaw A.T., Bauer T.M., de Marinis F., et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020;383(21):2018–29. doi: 10.1056/NEJMoa2027187.
  19. Solomon B.J., Bauer T.M., Mok T.S.K., et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023;11(4):354–66. doi: 10.1016/S2213-2600(22)00437-4.
  20. Mazieres J., Iadeluca L., Shaw A.T., et al. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer. 2022;174:146–56. doi: 10.1016/j.lungcan.2022.11.004.
  21. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non-Small Cell Lung Cancer. Version 3.2023– april 13, 2023.
  22. Hendriks L.E., Kerr K.M., Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358–76. doi: 10.1016/j.annonc.2022.12.013.
  23. Министерство Здравоохранения РФ. Клинические рекомендации «Злокачественное новообразование бронхов и легкого». Год утверждения: 2022. [Ministry of Health of the Russian Federation. Clinical recommendations «Malignant neoplasm of the bronchi and lung». Year of approval: 2022. (In Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.

Download (223KB)
Indexing metadata

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies